BridgeBio announced the first participant has been dosed in the ASCEND-ATTR Phase 3b/4 study evaluating acoramidis for disease regression in ATTR-CM.

BridgeBio has disclosed a secondary offering of 5 million shares by an affiliate of KKR.

BridgeBio Pharma has secured up to $1 billion in preferred equity financing from investment firms KKR and Sixth Street, bolstering its financial position.

BridgeBio has received a downgrade from Raymond James, attributed to the loss of exclusivity for Pfizer's drug Vyndamax.

BridgeBio Oncology Therapeutics, Inc. has reported a GAAP EPS of -$526.11 for its latest financial period.

Billionaire investor Tom Steyer has reportedly increased his holdings in several companies, including tech giants like Microsoft and Amazon, and various pharmaceutical firms. His recent investment activities indicate a bullish outlook on these specific stocks.

BridgeBio (BBIO) shares surged by 13% after receiving a double-digit price target upgrade, indicating increased investor confidence in the company's financial outlook.

BridgeBio Pharma reported record revenue for 2025, largely due to the commercial success of its drug Attruby.

BridgeBio Pharma's GAAP EPS of -$1.00 missed estimates by $0.33, though its revenue of $154.2 million beat by $5.13 million.

BridgeBio's stock has seen a significant 29% increase over the past three months, with analysts predicting further growth.

BridgeBio's stock experienced a significant jump following the announcement that a rival company's heart drug failed a crucial clinical trial.

Janux Therapeutics (JANX) is highlighted as a biotech opportunity with next-generation immunotherapy potential, while BridgeBio Oncology Therapeutics (BBOT) is seen as a rising oncology opportunity with KRAS G12C therapy potential. Both companies are attracting attention for their innovative approaches in the biotech sector.

Citi has begun its coverage of BridgeBio with a neutral rating, expressing caution about the company's cardiomyopathy story as a guaranteed success.

BridgeBio's stock experienced a decline even after the release of new data for its drug Attruby.

BridgeBio Pharmaceuticals saw gains after reaching a settlement in its patent dispute with Pfizer regarding the drug Vyndamax.

BridgeBio Oncology's stock has risen following the announcement that its asset for pancreatic cancer has been granted Fast Track status by the FDA, indicating an expedited review process for the drug.

Truist has raised its price target for BridgeBio Pharma, Inc. (BBIO) to $95, reiterating a Buy rating for the pharmaceutical company.

BridgeBio has outlined a strategic plan to achieve cash generation by 2028, targeting a $600 million profit driven by pipeline advancements and Attruby growth.

BridgeBio's secondary offering has been priced at $78 per share, as the company seeks to raise capital through the sale of additional stock.

Pfizer, Alnylam, and BridgeBio shares saw gains following a late-stage trial setback for AstraZeneca and Ionis.

BridgeBio's therapy for muscular dystrophy has been granted priority review by the FDA, potentially accelerating its path to market. This move indicates the FDA's recognition of the drug's potential to address an unmet medical need.

Evercore ISI has retained its "Outperform" rating on BridgeBio Pharma, Inc. (BBIO), indicating a positive outlook for the pharmaceutical company's stock.

This article provides key highlights from BridgeBio Pharma's first-quarter earnings call. The report covers financial performance and business updates for the period.

BridgeBio's stock saw gains following reports of a settlement in a patent dispute involving Pfizer's drug Vyndamax.

Mizuho has increased its price target for BridgeBio Pharma (BBIO) from $91 to $106, explaining the factors contributing to this revised target.

GH Research has reported a GAAP EPS of -$0.79 for its latest financial period.

BridgeBio Pharma's fourth-quarter earnings call provided insights into the company's recent financial performance and future outlook.